Mild Cognitive Impairment

• Amyloid-beta accumulation and tau pathology: In MCI due to Alzheimer's disease (most common subtype), pathologic hallmarks include extracellular amyloid-beta (Aβ42) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau. These lesions begin in the medial temporal lobe and entorhinal cortex, explaining the predominance of memory impairment. Biomarker evidence (decreased CSF Aβ42, elevated phosphorylated tau and total tau) reflects ongoing neurodegeneration even in preclinical stages.

• Progressive neurodegeneration and synaptic dysfunction: MCI involves selective vulnerability of hippocampal and cortical neurons, resulting in volumetric loss detectable on MRI. Neuronal loss is accompanied by synaptic dysfunction mediated by Aβ oligomers, which impair long-term potentiation and disrupt cholinergic and glutamatergic neurotransmission. Reduced glucose metabolism in the posterior cingulate cortex and precuneus (detectable on FDG-PET) reflects hypometabolism in vulnerable brain regions.

• Cerebrovascular and white matter changes: In MCI due to vascular cognitive impairment (VCI), small vessel disease produces white matter hyperintensities, lacunar infarcts, and loss of cerebral autoregulation. Mixed pathology (Alzheimer's and cerebrovascular disease) is common in older adults and accelerates cognitive decline. Chronic hypoperfusion and blood-brain barrier dysfunction contribute to neuroinflammation and additional neuronal loss.

Primary Etiologies (by frequency)

• MCI due to Alzheimer's disease (60-70% of cases): Preclinical or early Alzheimer's pathology with amnestic presentation predominating
• MCI due to vascular cognitive impairment (15-20%): Secondary to cerebrovascular disease, small vessel disease, or strategic infarcts
• MCI due to Lewy body disease (5-10%): Pathology related to alpha-synuclein; may present with visuospatial deficits or executive dysfunction
• MCI due to frontotemporal dementia (5%): Primary progressive aphasia or behavioral variant presentation; younger-onset typical
• MCI due to other causes: Parkinson's disease, traumatic brain injury sequelae, normal pressure hydrocephalus, vitamin B12 deficiency, hypothyroidism

Risk Factors for Development and Progression

• Age >65 years (strongest demographic risk)
• Apolipoprotein E4 (APOE4) genotype (dose-dependent risk for AD-related MCI)
• Cardiovascular risk factors: Hypertension, diabetes mellitus, hyperlipidemia, smoking, obesity
• History of traumatic brain injury with loss of consciousness
• Depression and mood disorders (bidirectional relationship; may precede cognitive decline)
• Low cognitive reserve: Limited education, minimal intellectual engagement, non-stimulating occupation
• Sleep disorders: Sleep apnea, insomnia, REM sleep behavior disorder (marker for Lewy body disease)
• Metabolic factors: Homocysteine elevation, metabolic syndrome, insulin resistance
• Genetic predisposition: Family history of dementia (especially early-onset), familial Alzheimer's disease mutations

Cardinal Features

• Objective memory loss (amnestic MCI): Patient or informant notes forgetfulness; typically affects episodic memory (recent events) more than semantic knowledge; performance on memory testing falls 1-1.5 standard deviations below age/education norms
• Non-amnestic cognitive deficits (30-40% of MCI cases): Executive dysfunction, visuospatial impairment, language difficulties, or processing speed reduction
• Preserved instrumental ADLs: Patient remains independent in medication management, financial handling, shopping, cooking, and transportation (key distinguishing feature from dementia)
• Subjective cognitive concerns: Often accompanied by awareness of difficulties ("anosognosia" absent, unlike late dementia)

Associated Symptoms and Signs

• Neuropsychiatric features: Apathy, anxiety, depression, irritability, or emotional lability (especially in non-amnestic variants)
• Gait abnormalities: Slowing, reduced stride length, or imbalance (particularly in vascular MCI and Lewy body-related MCI)
• Parkinsonian features: Bradykinesia, rigidity, tremor (in Lewy body disease; mild presentations may progress)
• Speech changes: Anomia (difficulty naming objects), word-finding difficulty, or dysarthria (language-predominant variants)
• Visuospatial deficits: Difficulty with complex visual tasks, navigation problems, or copying geometric figures
• Executive dysfunction: Poor problem-solving, reduced planning ability, impaired judgment (frontal-predominant)
• Normal basic neurologic examination: Cranial nerves, motor strength, reflex testing, and general sensory function typically intact

Clinical Diagnostic Criteria (Petersen, 2004; revised 2013)

1. 1.Concern about change in cognition (from patient, informant, or clinician observation)
2. 2.Objective impairment on cognitive testing (>1 SD below age/education norm in ≥1 domain)
3. 3.Preserved general cognitive function (MMSE typically ≥24/30)
4. 4.Preserved independence in complex ADLs
5. 5.Does not meet criteria for dementia

Cognitive Assessment Instruments

• Mini-Cognitive Assessment (Mini-Cog): Rapid 3-minute screening; 3-word delayed recall + clock drawing; sensitivity 76-99%, specificity 73-97% for cognitive impairment
• Montreal Cognitive Assessment (MoCA): More sensitive than MMSE for MCI detection; evaluates multiple domains (memory, visuospatial, executive, language, attention, orientation); score ≤25/30 suggests impairment
• Detailed neuropsychological testing: Gold standard; evaluates memory, executive function, language, visuospatial abilities, processing speed; identifies specific domain impairment patterns
• Clinical Dementia Rating (CDR) Scale: CDR 0.5 corresponds to MCI; differentiates from normal cognition (CDR 0) and mild dementia (CDR 1)

Laboratory Testing (to exclude reversible causes)

• Complete metabolic panel: Assess renal function, glucose, electrolytes (hyponatremia impairs cognition)
• Thyroid function tests (TSH, free T4): Hypothyroidism mimics cognitive impairment
• Vitamin B12 level and methylmalonic acid/homocysteine: Macrocytic anemia or elevated homocysteine indicates B12 deficiency
• Rapid plasma reagin (RPR) or FTA-ABS: Neurosyphilis screening
• HIV antibody testing: When clinically indicated by risk factors
• Apolipoprotein E genotyping: Not routinely recommended but may inform prognosis; APOE4 carriers have higher dementia conversion risk
• Cerebrospinal fluid biomarkers (when indicated): Decreased Aβ42, elevated phosphorylated tau and total tau; highly predictive of AD pathology but not standard diagnostic workup

Neuroimaging

• Structural MRI (preferred initial imaging): Assesses for hippocampal atrophy (medial temporal lobe atrophy score); excludes stroke, tumor, subdural hematoma, or normal pressure hydrocephalus; white matter hyperintensities quantified (Fazekas scale) in vascular MCI
• CT head: When MRI contraindicated; less sensitive for early changes but rules out acute stroke or mass
• Positron Emission Tomography (PET):
• FDG-PET: Shows hypometabolism in posterior cingulate, precuneus, and temporoparietal regions in AD-related MCI (not standard but useful when diagnosis uncertain)
• Amyloid-PET: Detects amyloid burden; positive in preclinical Alzheimer's disease
• Tau-PET: Emerging marker; correlates with neurodegeneration severity
• Amyloid-beta, tau, and phosphorylated tau on plasma biomarkers: Increasingly used; phosphorylated tau-181 and phosphorylated tau-217 show promise for AD pathway identification without lumbar puncture

Diagnostic Criteria by Subtype

• MCI due to AD: Amnestic presentation + MRI hippocampal atrophy + AD biomarkers (CSF or plasma Aβ42↓, tau↑, or amyloid/tau PET positivity)
• MCI due to vascular disease: Executive/processing speed deficits + vascular risk factors + white matter disease on MRI
• MCI-Lewy body: Visuospatial deficits ± parkinsonism + RBD history; may show occipital hypometabolism on PET
• Non-amnestic MCI: Deficits in non-memory domains with otherwise normal memory testing

Pharmacologic Treatment

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine):
• Mechanism: Reversible inhibition of acetylcholinesterase increases synaptic acetylcholine; also inhibit butyrylcholinesterase
• Evidence: Mixed results; some trials show modest slowing of decline, others show no benefit over placebo
• Dosing: Donepezil 5-10 mg daily (best-studied in MCI); rivastigmine 3-6 mg BID (1.5-6 mg/day patch); galantamine 8-12 mg BID
• Adverse effects: GI disturbance (nausea, diarrhea), bradycardia, syncope, vivid dreams; CI in sick sinus syndrome or AV block
• Role: Not FDA-approved for MCI; may be considered in amnestic MCI with AD biomarkers, particularly APOE4 carriers

• Memantine (NMDA receptor antagonist):
• Mechanism: Non-competitive NMDA glutamate receptor antagonist; reduces excitotoxicity
• Evidence: Limited benefit in isolated MCI; may provide additive benefit when combined with cholinesterase inhibitors
• Dosing: Start 5 mg daily; titrate to 10 mg BID over 4 weeks
• Role: Not first-line in MCI but consider in combination therapy

• Lecanemab (anti-amyloid monoclonal antibody):
• Mechanism: Binds protofibrils and other amyloid-beta conformers; promotes microglial clearance
• Evidence: Dominantly Inherited Alzheimer Network Trial (DIAN-TU) showed 35% slowing of decline in preclinical AD; FDA approved for cognitively normal amyloid-positive and MCI due to AD
• Dosing: 10 mg/kg IV infusion every 2 weeks (after loading phase)
• Monitoring: Requires amyloid-PET or CSF biomarker confirmation; APOE4 status influences amyloid-related imaging abnormalities (ARIA) risk
• Role: Emerging as early intervention in biomarker-confirmed AD pathology; ARIA-E (brain edema, 21% incidence) and ARIA-H (microhemorrhages) require MRI surveillance

• Aducanumab (anti-amyloid monoclonal antibody):
• Status: FDA accelerated approval withdrawn (2023) due to insufficient evidence of efficacy
• Historical note: Controversial approval based on amyloid reduction without clear cognitive benefit

Non-Pharmacologic Interventions (strongest evidence base)

• Cognitive training and mental stimulation:
• Mechanism: Engages cognitive reserve; neuroplasticity-based rehabilitation
• Evidence: Moderate evidence for computerized cognitive training (n-back tasks, working memory exercises); benefits may not transfer to untrained domains
• Implementation: 15-30 minutes, 3-5 times/week; programs like BrainHQ, Lumosity, or clinician-guided training
• Duration: Benefit requires ongoing engagement; effects diminish upon cessation

• Physical exercise (most robust evidence):
• Mechanism: Increases BDNF, improves cerebral blood flow, reduces neuroinflammation, enhances hippocampal volume
• Evidence: Aerobic exercise 150 minutes/week moderate intensity associated with cognitive stabilization and reduced dementia progression (prospective cohort data)
• Types: Brisk walking, swimming, cycling, tai chi, resistance training
• Dosing: ≥150 minutes/week aerobic activity or equivalent resistance training
• Monitoring: Baseline exercise tolerance assessment; gradual progression to avoid orthostatic hypotension or cardiac events

• Diet and nutritional optimization:
• DASH and Mediterranean diets: Prospective evidence for reduced cognitive decline; anti-inflammatory, reduce amyloid burden
• B vitamins: Controversial; high-dose folic acid, B6, B12 may reduce homocysteine but no proven cognitive benefit in MCI
• Omega-3 fatty acids: Docosahexaenoic acid (DHA) 2 g daily shows weak evidence for benefit
• Implementation: Emphasize leafy greens, fish, olive oil, whole grains; limit saturated fat and processed foods

• Sleep optimization:
• Mechanism: Glymphatic clearance of amyloid-beta and tau during NREM sleep; sleep deprivation increases AD biomarker levels
• Evidence: Sleep apnea treatment (CPAP) may stabilize cognition; insomnia treatment with CBT-I shows promise
• Goal: 7-9 hours nightly; regular sleep-wake schedule; screening for sleep disorders

• Cognitive and social engagement:
• Mechanism: Builds cognitive reserve; social interaction reduces depression and neuroinflammation
• Evidence: Engagement in cognitively stimulating activities (reading, puzzles, learning) and regular social contact associated with slower decline
• Implementation: Learning new skills, volunteer work, group activities, grandparenting; minimize television and passive activities

• Cardiovascular risk factor management:
• Hypertension control: Target BP <130/80 mmHg (SPRINT MIND trial); antihypertensives reduce dementia incidence
• Diabetes management: Tight glucose control (HbA1c <7%); metformin shows potential neuroprotective effects
• Lipid management: Statins in secondary prevention; evidence mixed for primary prevention
• Smoking cessation: Essential; smoking accelerates cognitive decline
• Weight management: BMI 20-25 associated with better cognitive outcomes

Monitoring and Follow-up

• Cognitive reassessment: Annually or every 6-12 months with standardized instruments (MoCA, MMSE, or formal neuropsych testing)
• Functional assessment: CDR rating, ADL scales to detect progression to dementia
• Neuroimaging: Repeat MRI at baseline and 2-3 years to assess progression of atrophy or white matter changes; more frequent if clinical decline
• Biomarker monitoring: Repeat CSF or plasma tau/phosphorylated tau if available; amyloid-PET if considering anti-amyloid therapy
• Depression and mood screening: PHQ-9 annually; treat depression aggressively

• Progression to dementia: Annual conversion rate 10-15% (range 5-30% depending on etiology, age, biomarker status); higher in amnestic MCI with AD biomarkers and APOE4 status. Management: Intensify cognitive monitoring, neuroimaging surveillance, consider anti-amyloid therapy if biomarker-confirmed AD.

• Falls and injuries: Secondary to executive dysfunction, visuospatial deficits, gait slowing, and increased fall risk in Lewy body-related and vascular MCI. Management: Home safety assessment, physical therapy, vestibular rehabilitation, medication review

The defining discriminator

• Function, not test score, separates MCI from dementia: objective decline on testing with preserved independence in instrumental ADLs. If the patient can no longer manage medications, finances, or transportation without help, the answer is dementia (major neurocognitive disorder, DSM-5-TR), not MCI.
• A normal MMSE does not exclude MCI: the MMSE is weighted toward orientation and lacks executive/delayed-recall sensitivity. The MoCA detects the executive and memory-retrieval deficits that define early impairment — a classic stem is a professional with a "normal" MMSE but an abnormal MoCA.

Single best next step

• Search for reversible contributors before labeling neurodegeneration: TSH, B12, metabolic panel, depression screening, and — most commonly missed — a medication review. Anticholinergics (diphenhydramine, oxybutynin, TCAs), benzodiazepines, opioids, and sedative-hypnotics are the highest-yield reversible cause on exams. Deprescribing is explicitly endorsed by the American Academy of Neurology 2018 MCI practice guideline update.
• Structural imaging (MRI preferred) is obtained to exclude subdural hematoma, tumor, strategic infarct, and normal pressure hydrocephalus — not to "confirm" MCI.

The association examiners test

• Amnestic MCI predicts conversion to Alzheimer disease; non-amnestic subtypes point toward Lewy body disease (visuospatial deficits, REM sleep behavior disorder), frontotemporal degeneration, or vascular cognitive impairment.
• APOE4 raises risk in a dose-dependent fashion but is neither diagnostic nor routinely recommended for testing (AAN); it is a risk modifier and an ARIA risk factor if anti-amyloid therapy is considered.

Distractors to avoid

• Not normal aging: benign age-related forgetfulness does not produce performance below age- and education-matched norms.
• Not delirium: delirium is acute with fluctuating attention and altered arousal; MCI has a preserved sensorium.
• Depression can masquerade as MCI and can coexist — treat mood before attributing decline to neurodegeneration.
• MCI is not uniformly progressive: a meaningful minority revert to normal cognition, so avoid answers that promise inevitable dementia.
• No symptomatic drug is approved for MCI: neither cholinesterase inhibitors nor memantine carry an FDA indication for MCI. The only approved pharmacotherapy in this population is anti-amyloid immunotherapy (lecanemab, donanemab) for biomarker-confirmed MCI due to Alzheimer disease.
• Exercise carries the strongest AAN 2018 recommendation (regular exercise, twice weekly; Level B); cognitive training is offered a weaker Level C recommendation.
• USPSTF finds evidence insufficient (I statement) to screen asymptomatic older adults for cognitive impairment.